For years, Novo Nordisk was the poster child of growth. Its GLP-1 drugs, Ozempic and Wegovy, didn’t just change obesity treatment — they reshaped the company’s balance sheet. Demand outpaced supply, public awareness skyrocketed, and Novo’s market cap surged.
But growth always attracts challengers. Enter Eli Lilly with Mounjaro and Zepbound, and a wave of competitors and compounded generics threatening margins. Add in slowing sales growth and operational bloat from years of expansion, and suddenly Novo’s leadership had to answer tough questions about sustainability.
Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of different companies, brands and therapy areas in the Indian Pharmaceutical Market.
Editor's Note - This issue of MedicinMan is dedicated to the memory of Dr. Tarun Gupta, TG as he was fondly called. Executive Editor, Salil Kallianpur, dear friend Subrato Banerjee and long-time MedicinMan patron Vivek Hattangadi, pen their tributes to TG.
BrandStorm is the annual event for Pharma Brand Managers. The event features thought leaders in pharma brand management addressing the hottest topics of the day.
Past topics include:
UCPMP & MCI Guidelines – Implication for Pharma Marketing
Brand Building: Case Studies from the Indian Pharma Market
Unleashing the Power of Digital Marketing – Case Studies
From Brand Management to Therapy Shaping
Marketing to Hospitals
Case Study Zifi-AZ
Field Force – Doctor Interaction through use of Digital and Social Media
How to Optimise Healthcare Communication Creative Agency Services
Past Speakers include:
PV Sankar Dass – CEO & Director, CURATIO
Darshan Patel – Partner, Pricewaterhouse Coopers
Daleep Manhas – General Manager & Associate Vice President at McCann Health
